Dual AAV-mediated gene therapy restores hearing in a DFNB9 mouse model - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Proceedings of the National Academy of Sciences of the United States of America Année : 2019

Dual AAV-mediated gene therapy restores hearing in a DFNB9 mouse model

Paul Avan

Résumé

Autosomal recessive genetic forms (DFNB) account for most cases of profound congenital deafness. Adeno-associated virus (AAV)-based gene therapy is a promising therapeutic option, but is limited by a potentially short therapeutic window and the constrained packaging capacity of the vector. We focus here on the otoferlin gene underlying DFNB9, one of the most frequent genetic forms of congenital deafness. We adopted a dual AAV approach using two different recombinant vectors, one containing the 5' and the other the 3' portions of otoferlin cDNA, which exceed the packaging capacity of the AAV when combined. A single delivery of the vector pair into the mature cochlea of Otof -/- mutant mice reconstituted the otoferlin cDNA coding sequence through recombination of the 5' and 3' cDNAs, leading to the durable restoration of otoferlin expression in transduced cells and a reversal of the deafness phenotype, raising hopes for future gene therapy trials in DFNB9 patients.
Fichier principal
Vignette du fichier
4496.full.pdf (1.69 Mo) Télécharger le fichier
Origine : Publication financée par une institution
Loading...

Dates et versions

hal-02318673 , version 1 (25-10-2019)

Licence

Paternité - Pas d'utilisation commerciale - Pas de modification

Identifiants

Citer

Omar Akil, Frank M. Dyka, Charlotte Calvet, Alice Emptoz, Ghizlene Lahlou, et al.. Dual AAV-mediated gene therapy restores hearing in a DFNB9 mouse model. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116 (10), pp.4496-4501. ⟨10.1073/pnas.1817537116⟩. ⟨hal-02318673⟩
256 Consultations
65 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More